Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Cergutuzumab amunaleukin |
Trade Name | |
Synonyms | RO6895882|RG7813|CEA TCB|RG-7813 |
Drug Descriptions |
Cergutuzumab amunaleukin (RG7813) is a bispecific antibody that binds carcinoembyronic antigen (CEA) and CD3, potentially resulting in enhanced T-cell response to CEA-expresssing tumor cells (European Journal of Cancer, Volume 51, Supplement 1, March 2015, Page S13, PMID: 28405498). |
DrugClasses | CD3 Antibody 99 |
CAS Registry Number | 1509916-03-3 |
NCIT ID | C141459 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cergutuzumab amunaleukin | Cergutuzumab amunaleukin | 0 | 2 |